(Q34453350)

2 August 2017

1 reference

title

Epoetin alfa in cancer patients: evidence-based guidelines (English)

1 reference

2 August 2017

R Turner

1

1 reference

2 August 2017

P Anglin

2

1 reference

2 August 2017

R Burkes

3

1 reference

2 August 2017

F Couture

4

1 reference

2 August 2017

W Evans

5

1 reference

2 August 2017

G Goss

6

1 reference

2 August 2017

R Grimshaw

7

1 reference

2 August 2017

B Melosky

8

1 reference

2 August 2017

A Paterson

9

1 reference

2 August 2017

I Quirt

10

1 reference

2 August 2017

Canadian Cancer and Anemia Guidelines Development Group

11

1 reference

2 August 2017

publication date

1 November 2001

1 reference

Journal of Pain and Symptom Management

2 August 2017

published in

1 reference

2 August 2017

volume

22

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

954-965

1 reference

A Canadian survey of cancer patients' experiences: are their needs being met?

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Chemotherapy-induced anemia in adults: incidence and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

1 reference

7 January 2021

Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

The significance of anemia in clinical radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study)

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

Recombinant human erythropoietin treatment for chemotherapy-related anemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900357-8

7 January 2021

10.1016/S0885-3924(01)00357-8

Identifiers

DOI

1 reference

2 August 2017

1 reference